Business Wire

Colt harnesses ADVA FSP 3000 for quantum-secured transport in live network trial

Share

ADVA (FSE: ADV) today announced that Colt Technology Services has successfully conducted a field trial of quantum-secured transport using its FSP 3000 platform with ConnectGuard™ Layer 1 encryption technology. The trial utilized quantum key distribution (QKD) to super-encrypt live data traffic, demonstrating how mission-critical services can be protected even against large-scale attacks. Conducted over Colt’s deployed metro network in Frankfurt, the demo shows how enterprise customers can achieve secure cloud access and robustly protect sensitive data in the long term. ADVA’s partner ID Quantique also played a key role in the trial.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210216005179/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ADVA’s ConnectGuard™ technology helps Colt showcase the future of quantum-safe networking (Photo: Business Wire)

“With quantum computers on the horizon, it’s crucial to stay one step ahead of the hackers. This trial is a major step towards the next generation of cryptographic infrastructure and takes us closer to safeguarding our customers’ information from tomorrow’s threats,” said Oktay Tekin, director, sales engineers, DACH, Colt Technology Services. “Businesses across the world depend on the speed, reliability and robust security of our services to operate effectively and with complete peace of mind. By conducting this trial with ADVA to harness QKD technologies, we’re exploring how to protect against unprecedented challenges further down the line.”

Widely predicted to be vital to the future of network security, QKD offers the ultimate defense against eavesdropping attacks. Using the laws of physics to create tamper-proof encryption keys, it protects traffic from all threats, including data harvesting for future quantum hacking. Colt’s trial harnessed the ADVA FSP 3000, which receives quantum keys generated by ID Quantique’s QKD technology. The QKD provides quantum random bit strings. These keys are used as an additional entropy source for the ADVA encryption solution, operating at line speeds of 100Gbit/s. The solution is the first commercial high-speed optical networking product to feature a dedicated interface for quantum keys based on the ETSI key delivery standard.

“Our FSP 3000 ConnectGuard™ encryption solution ensures maximum security as well as high capacity and low latency. In recent years, it has won a fierce reputation for protecting service provider and enterprise networks across the globe. Now, this trial of QKD-secure transport is proving how vital our technology will be even in the post-quantum era,” commented Uli Schlegel, director, product line management, ADVA. “Colt’s trial shows that it’s now possible to secure high-speed connectivity over deployed operational networks against tomorrow’s quantum computer attacks. It’s a significant milestone for Colt’s enterprise customers. From sensitive financial information to valuable intellectual property, their data will soon be shielded from the cybercriminals of the future.”


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

About Colt
Colt strives to transform the way the world works through the power of connectivity - taking what’s always been in its DNA to enable customers’ success. The Colt IQ Network connects more than 900+ data centres and over 29,000 on net buildings across Europe, Asia and North America’s largest business hubs.Colt understands today’s shifting connectivity requirements and provides agile, on-demand and secure high bandwidth networking and voice solutions to ensure enterprises can thrive. Customers include data-intensive organisations spanning over 210 cities in more than 30 countries. Colt is a recognised innovator and pioneer in Software Defined Networks (SDN) and Network Function Virtualisation (NFV). Privately owned, Colt is one of the most financially sound companies in the sector, and because of this, it’s able to put its customers’ needs at its core. For more information, please visit www.colt.net.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye